Pharmacological Approach for Treatment of Retinopathy of Prematurity
Current standard of screening examination for retinopathy of prematurity (ROP) is determined in international guidelines. The criteria for classification and therapy are also determined in international guidelines, and currently, retinal laser fotocoagulation of peripheral avascular retinal area i...
| 出版年: | Türk Oftalmoloji Dergisi |
|---|---|
| 第一著者: | |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Turkish Ophthalmology Society
2012-12-01
|
| 主題: | |
| オンライン･アクセス: | http://www.oftalmoloji.org/article_2213/Pharmacological-Approach-For-Treatment-Of-Retinopathy-Of-Prematurity |
| 要約: | Current standard of screening examination for retinopathy of prematurity (ROP) is determined in international guidelines. The criteria for
classification and therapy are also determined in international guidelines, and currently, retinal laser fotocoagulation of peripheral avascular
retinal area is gold standard (ETROP, Early Treatment for Retinopathy of Prematurity Cooperative Group) for proliferative ROP. Vitreoretinal
surgery will be used in cases with retinal detachment. In case series after off-label injection of anti-VEGF (vascular endothelial growth factor)
agent bevacizumab and in the first report of BEAT-ROP study in proliferative ROP the results are promising. Furthermore, beside the
intravitreal anti-VEGF therapy, systemic therapy with mediators like IGF-1 (insulin-like growth factor) and/or ω3-fatty acids outlines
pharmacological approach to treatment of ROP. The results of well-designed clinical trials of intravitreal anti-VEGF therapy and
pharmacological systemic therapy with the above-mentioned mediators for ROP are needed in order to provide information as to the balance of
risk versus benefit, as well as practical guidance regarding optimal treatment parameters and follow-up.(Turk J Ophthalmol 2012; 42: 466-73) |
|---|---|
| ISSN: | 1300-0659 2147-2661 |